Rosacea & the Skin-Gut Microbiome Axis

Overview

Rosacea is a chronic inflammatory skin condition primarily affecting the central face, characterized by persistent erythema, flushing, telangiectasia (visible blood vessels), papules, and pustules. The condition affects an estimated 16 million Americans and up to 5% of the global adult population, with a predilection for individuals of Northern European descent and fair complexion, though it is likely underdiagnosed in darker skin tones. Rosacea can significantly impact quality of life, causing both physical discomfort and psychosocial distress.^[1]

While the pathogenesis of rosacea is not fully understood, it involves a complex interplay of innate immune dysregulation, neurovascular changes, and microbial factors. The role of microorganisms in rosacea has garnered increasing attention, with research revealing connections not only to skin-resident organisms but also to the gut microbiome through the gut-skin axis. The consistent association between rosacea and gastrointestinal conditions -- including small intestinal bacterial overgrowth (SIBO), Helicobacter pylori infection, and inflammatory bowel disease -- suggests that systemic microbial imbalances may contribute to disease pathogenesis beyond what can be explained by local skin factors alone.^[2]

Understanding the microbial dimensions of rosacea may open new avenues for management beyond traditional topical and systemic therapies, particularly for patients who experience incomplete relief from conventional approaches.^[3]

Key Takeaways

• Rosacea affects an estimated 16 million Americans and involves both skin and gut microbiome dysregulation through the gut-skin axis
• Demodex folliculorum mites are found at up to 15-fold higher density on rosacea-affected skin, and their associated bacterium Bacillus oleronius may be the primary inflammatory trigger
• Approximately 46% of rosacea patients test positive for SIBO, and SIBO eradication has been shown to significantly improve or resolve rosacea lesions in clinical studies
• A large population-based cohort study found that rosacea patients have significantly elevated risks of celiac disease, Crohn's disease, ulcerative colitis, and other gastrointestinal conditions
• Addressing both skin and gut microbiome imbalances may offer a more comprehensive approach to rosacea management than targeting the skin alone

The Microbiome Connection

Demodex Mites and Cutaneous Dysbiosis

On the skin, Demodex mites (primarily Demodex folliculorum) are found in significantly higher densities on rosacea-affected skin compared to healthy controls -- up to 15 times greater in some studies. These microscopic mites reside in hair follicles and sebaceous glands, and their overpopulation has been linked to the inflammatory papules and pustules characteristic of the condition. Importantly, the bacteria associated with Demodex, particularly Bacillus oleronius, may be the primary inflammatory trigger rather than the mites themselves. Proteins from B. oleronius have been shown to activate neutrophilic and perivascular inflammation in rosacea skin, and antibodies against this organism are elevated in rosacea patients and correlate with disease severity.^[4][3]

Small Intestinal Bacterial Overgrowth (SIBO)

The gut-skin axis represents a significant dimension of rosacea pathogenesis. Parodi and colleagues demonstrated in a landmark study that 46% of rosacea patients had SIBO, compared to only 5% of controls. SIBO involves excessive bacterial colonization of the small intestine, which triggers local and systemic inflammatory responses through production of pro-inflammatory cytokines, increased intestinal permeability, and immune activation. Treatment with rifaximin to eradicate SIBO resulted in significant improvement or complete resolution of rosacea lesions in the majority of patients, while those who did not have SIBO showed less improvement with the same treatment.^[5] A three-year follow-up study confirmed that skin improvements were maintained in patients who remained SIBO-free, providing strong evidence for a sustained causal relationship.^[6]

Helicobacter pylori and Gastrointestinal Comorbidities

Helicobacter pylori infection has also been associated with rosacea, potentially through the production of cytotoxins and reactive oxygen species that may contribute to systemic inflammation and vascular changes. Some studies have shown improvement in rosacea symptoms following H. pylori eradication therapy, though the evidence remains mixed.^[7] A large population-based cohort study by Egeberg and colleagues, analyzing over 49,000 rosacea patients, found significantly elevated risks of celiac disease, Crohn's disease, ulcerative colitis, and other gastrointestinal conditions, providing robust epidemiological support for the gut-skin axis hypothesis in rosacea.^[2]

Key Microorganisms

Demodex folliculorum (skin mite)

• Impact: Found at dramatically increased densities on rosacea-affected skin; serves as a vector for inflammatory bacteria and may directly contribute to follicular inflammation and immune activation
• Function: Harbors Bacillus oleronius within its body, which is released upon mite death; the resulting bacterial proteins trigger TLR2-mediated inflammatory responses, neutrophil recruitment, and the characteristic papulopustular lesions of rosacea^[4]

Bacillus oleronius (Demodex-associated bacterium)

• Impact: Proteins from this bacterium stimulate peripheral blood mononuclear cell proliferation and inflammatory cytokine release in rosacea patients; antibody levels against B. oleronius correlate with disease severity
• Function: Produces antigens that trigger both innate and adaptive immune responses in the skin, contributing to the chronic inflammatory state that characterizes rosacea^[3]

Helicobacter pylori

• Impact: Found at elevated prevalence in some rosacea populations; its eradication has been associated with rosacea improvement in some but not all clinical studies
• Function: Produces cytotoxin-associated gene A (CagA) protein and reactive oxygen species that may promote systemic inflammation, increased vascular permeability, and the neurovascular changes characteristic of rosacea flushing^[7]

Lactobacillus rhamnosus GG

• Impact: May help modulate the gut-skin axis inflammatory signaling that contributes to rosacea; supports intestinal barrier integrity to reduce systemic immune activation originating from the gut
• Function: Strengthens epithelial tight junctions, promotes anti-inflammatory cytokine production, and may help prevent or reduce the SIBO that is commonly found in rosacea patients^[5]

Microbiome-Based Management Strategies

Demodex-Targeted Skin Treatments

For the skin microbiome, treatments that reduce Demodex populations have demonstrated efficacy in clinical trials. Topical ivermectin (1% cream) has become a first-line treatment for papulopustular rosacea, working in part through its anti-parasitic effects on Demodex mites. Topical metronidazole also reduces Demodex density while providing anti-inflammatory benefits. Gentle skin care that preserves the skin barrier and avoids disrupting the commensal microbiome may complement these targeted anti-parasitic treatments.^[4] Evidence Level: Strong (for topical ivermectin and metronidazole)

SIBO Testing and Eradication

Addressing potential gut dysbiosis may be particularly important for rosacea patients with concurrent gastrointestinal symptoms. Testing for SIBO through hydrogen breath testing and treating it when present has shown significant benefit for skin symptoms, with improvements maintained at three years in patients who remained SIBO-free.^[5][6] H. pylori testing and eradication may also be considered for patients with upper gastrointestinal symptoms. Evidence Level: Moderate to Strong (for SIBO eradication); Preliminary (for H. pylori eradication)

Gut-Supportive Probiotic Supplementation

Probiotic supplementation with strains such as Lactobacillus rhamnosus GG, Bifidobacterium longum, and Lactobacillus plantarum may help support gut barrier integrity and modulate the systemic immune activation that contributes to facial inflammation. While large-scale rosacea-specific probiotic trials are limited, the strong evidence linking gut dysbiosis to rosacea suggests that supporting gut health may complement skin-targeted therapies.^[1] Evidence Level: Preliminary

Dietary Trigger Management and Anti-Inflammatory Nutrition

Some rosacea patients report that identifying and avoiding specific dietary triggers, such as spicy foods, alcohol, and histamine-rich foods, helps reduce flares. Beyond trigger avoidance, a fiber-rich, anti-inflammatory dietary pattern may help address the underlying gut-skin axis dysregulation common to many rosacea patients. The Mediterranean diet pattern, rich in polyphenols and omega-3 fatty acids, has been proposed as a supportive dietary framework. Stress management is also relevant, as psychological stress appears to exacerbate both gut dysbiosis and rosacea symptoms through shared neuroimmune pathways.^[8] Evidence Level: Preliminary to Moderate (for trigger avoidance); Preliminary (for anti-inflammatory diet)

Future Directions

The dual-microbiome nature of rosacea -- involving both skin and gut -- makes it a uniquely interesting condition for microbiome research. Future studies are investigating whether microbiome profiling of both skin and gut could improve rosacea subtype classification and guide more personalized treatment approaches. Topical microbiome-modulating therapies, including bacteriophages that selectively target Demodex-associated bacteria without disrupting beneficial skin commensals, represent a promising area of development.

The strong evidence linking SIBO to rosacea has prompted interest in whether gut microbiome restoration following SIBO eradication could provide more durable remission than antimicrobial treatment alone. Combination approaches that simultaneously address skin Demodex overgrowth, gut SIBO, and systemic inflammation through integrated microbiome strategies may ultimately prove more effective than treatments targeting any single component.

Rosacea diagnosis and management should involve a dermatologist, and individuals experiencing persistent facial redness, papules, or eye irritation should seek professional evaluation. Gastrointestinal testing may be warranted for rosacea patients with digestive symptoms, and microbiome-supportive strategies should be discussed with a healthcare provider as part of an integrated treatment plan.